Clinical trials sponsored by Shu Wang
7
Recruiting trials
3
Conditions studied
Phase breakdown
Not applicable 7
Conditions studied
| Condition | Trials |
|---|---|
| Breast cancer | 7 |
| HER2-positive Breast Cancer | 6 |
| Triple Negative Breast Cancer | 1 |
Recruiting trials led by Shu Wang
- Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
- Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
- Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
- Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
- Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
- Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
Common questions
How many trials is Shu Wang recruiting for?
Shu Wang is the lead sponsor of 7 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.